Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Immunol ; 171(6): 2945-52, 2003 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-12960318

RESUMEN

In a variety of malignancies, the immune-escape phenotype is associated, in part, with the inability of tumor cells to properly present their Ags to CTLs due to a deranged expression of MHC class I glycoproteins. However, these molecules were found to possess broader nonimmune functions, including participation in signal transduction and regulation of proliferation, differentiation, and sensitivity to apoptosis-inducing factors; processes, which are characteristically impaired during malignant transformation. We investigated whether the deranged expression of MHC class I expression by tumor cells could affect proper receptor-mediated signal transduction and accentuate their malignant phenotype. The malignant and H-2K murine MHC class I-deficient B16BL6 melanoma cells were characterized by an attenuated capacity to bind insulin due to the retention of corresponding receptor in intracellular stores. The restoration of H-2K expression in these cells, which abrogated their capacity to form tumors in mice, enhanced membrane translocation of the receptor, presumably, by modulating its glycosylation. The addition of insulin to H-2K-expressing melanoma cells cultured in serum-free conditions precluded apoptotic death by up-regulating the activity of protein kinase B (PKB)/Akt. In contrast, the deficiency for H-2K characteristic to the malignant clones was associated with a constitutive high activity of PKB/Akt, which rendered them resistant to apoptosis, induced by deprivation of serum-derived growth factors. The possibility to correct the regulation of PKB/Akt activity by restoration of H-2K expression in B16BL6 melanoma cells may be considered as an attractive approach for cancer therapy, since an aberrant activation of this enzyme is characteristic to resistant malignancies.


Asunto(s)
Adyuvantes Inmunológicos/fisiología , Apoptosis/inmunología , Glicoproteínas/biosíntesis , Antígenos H-2/biosíntesis , Melanoma Experimental/inmunología , Melanoma Experimental/metabolismo , Proteínas Serina-Treonina Quinasas , Receptor de Insulina/fisiología , Transducción de Señal/inmunología , Adyuvantes Inmunológicos/biosíntesis , Adyuvantes Inmunológicos/genética , Adyuvantes Inmunológicos/metabolismo , Animales , Línea Celular Tumoral , Células Clonales , Glicoproteínas/genética , Glicoproteínas/metabolismo , Glicoproteínas/fisiología , Glicosilación , Sustancias de Crecimiento/deficiencia , Antígenos H-2/genética , Antígenos H-2/metabolismo , Antígenos H-2/fisiología , Inmunidad Innata , Insulina/metabolismo , Melanoma Experimental/enzimología , Ratones , Ratones Endogámicos C57BL , Unión Proteica/inmunología , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-akt , Receptor de Insulina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA